Skip to main content

Advertisement

Log in

Statin Therapy in Heart Failure: For Good, for Bad, or Indifferent?

  • Statin Drugs (MB Clearfield, Section Editor)
  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

Statins are effective in the prevention of coronary events and the treatment of acute coronary syndromes. However, their efficacy and safety in patients with heart failure (HF) is still a matter of debate. On the basis of literature evidence from subgroup analysis, retrospective, prospective cohort studies, and randomized controlled trials, in this review we try to answer the following question: Is statin therapy in HF patients for good, for bad, or indifferent? Some studies showed a negative impact of low cholesterol levels in patients with severe HF (endotoxin–lipoprotein hypothesis and coenzyme Q10 hypothesis). On the other hand, a large amount of literature demonstrates that in patients with HF, statins have a positive impact on survival and other outcomes, regardless of whether the HF was of ischemic or nonischemic origin, which is related to a combination of mechanisms (pleiotropic effects and cholesterol reduction). Much of this evidence, however, comes from observational and retrospective studies and subgroup analyses of statin use in patients with HF. Randomized clinical trials examining the efficacy of statins in HF (GISSI-HF and CORONA) did not show a benefit in mortality for patients with HF randomized to receive statins. Nevertheless, a meta-analysis found that statin therapy does not decrease all-cause or cardiovascular mortality but significantly decreases the rate of hospitalization for worsening HF and increased left ventricular ejection fraction compared with placebo.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Scandinavian Simvastatin Survival Study Investigators. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–9.

    Google Scholar 

  2. Mason JM, Freemantle N. Coronary events with lipid-lowering therapy: the AFCAPS/TexCAPS trial. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1999;281:415–6.

    Article  CAS  PubMed  Google Scholar 

  3. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001–9.

    Article  CAS  PubMed  Google Scholar 

  4. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301–7.

    Article  CAS  PubMed  Google Scholar 

  5. Brunetti ND, Maulucci G, Casavecchia GP, Distaso C, De Gennaro L, Pellegrino PL, et al. Improvement in endothelium dysfunction in diabetics treated with statins: a randomized comparison atorvastatin 20 mg vs. rosuvastatin 10 mg. J Interv Cardiol. 2007;20:481–7.

    Article  PubMed  Google Scholar 

  6. Chan AW, Bhatt DL, Chew DP, Quinn MJ, Moliterno DJ, Topol EJ, et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation. 2002;105:691–6.

    Article  CAS  PubMed  Google Scholar 

  7. McGirt M, Perler B, Brooke B, McGirt MJ, Perler BA, Brooke BS, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors reduce the risk of perioperative stroke and mortality after carotid endarterectomy. J Vasc Surg. 2005;42:829–36.

    Article  PubMed  Google Scholar 

  8. Yasuda H, Yuen P, Hu X, Zhou H, Star R. Simvastatin improves sepsis-induced mortality and acute kidney injury via renal vascular effects. Kidney Int. 2006;69:1535–42.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Vrtovec B, Okrajsek R, Golicnik A, Ferjan M, Starc V, Schlegel TT, et al. Atorvastatin therapy may reduce the incidence of sudden cardiac death in patients with advanced chronic heart failure. J Card Fail. 2008;14:140–4.

    Article  CAS  PubMed  Google Scholar 

  10. Sola S, Mir MQ, Lerakis S, Tandon N, Khan BV. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol. 2006;47:332–7.

    Article  CAS  PubMed  Google Scholar 

  11. Yamada T, Node K, Mine T, Morita T, Kioka H, Tsukamoto Y, et al. Long-term effect of atorvastatin on neurohumoral activation and cardiac function in patients with chronic heart failure: a prospective randomized controlled study. Am Heart J. 2007;153(Suppl):e1051–8.

    Google Scholar 

  12. Node K, Fujita M, Kitakaze M, Hori M, Liao JK. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation. 2003;108:839–43.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Wojnicz R, Wilczek K, Nowalany-Kozielska E, Szyguła-Jurkiewicz B, Nowak J, Poloński L, et al. Usefulness of atorvastatin in patients with heart failure due to Inflammatory dilated cardiomyopathy and elevated cholesterol levels. Am J Cardiol. 2006;97:899–904.

    Article  CAS  PubMed  Google Scholar 

  14. Xie RQ, Cui W, Liu F, Yang C, Pei WN, Lu JC. Statin therapy shortens QTc, QTcd, and improves cardiac function in patients with chronic heart failure. Int J Cardiol. 2010;140:255–7.

    Article  PubMed  Google Scholar 

  15. Tavazzi L, Tognoni G, Franzosi MG, Latini R, Maggioni AP, Marchioli R, et al. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail. 2004;6:635–41.

    CAS  PubMed  Google Scholar 

  16. Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, Cornel JH, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248–61.

    Article  CAS  PubMed  Google Scholar 

  17. Horwich TB, Hamilton MA, Maclellan WR, Fonarow GC. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail. 2002;8:216–24.

    Article  CAS  PubMed  Google Scholar 

  18. Rauchhaus M, Clark A, Doehner W, Davos C, Bolger A, Sharma R, et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol. 2003;42:1933–40.

    Article  CAS  PubMed  Google Scholar 

  19. Go A, Lee W, Yang J, Lo J, Gurwitz J. Statin therapy and risks of death and hospitalization in chronic heart failure. JAMA. 2006;296:2105–11.

    Article  CAS  PubMed  Google Scholar 

  20. May HT, Muhlestein JB, Carlquist JF, Horne BD, Bair TL, Campbell BA, et al. Relation of serum total cholesterol, C-reactive protein levels, and statin therapy to survival in heart failure. Am J Cardiol. 2006;98:653–8.

    Article  CAS  PubMed  Google Scholar 

  21. Rauchhaus M, Koloczek V, Volk H, Kemp M, Niebauer J, Francis DP, et al. Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure. Int J Cardiol. 2000;76:125–33.

    Article  CAS  PubMed  Google Scholar 

  22. Soja AM, Mortensen SA. Treatment of congestive heart failure with coenzyme Q10 illuminated by meta-analyses of clinical trials. Mol Asp Med. 1997;18(Suppl):S159–68.

    Article  CAS  Google Scholar 

  23. Rauchova H, Drahota Z, Lenaz G. Function of coenzyme Q in the cell: some biochemical and physiological properties. Physiol Res. 1995;44:209–16.

    CAS  PubMed  Google Scholar 

  24. Cohn JN, Johnson GC, Shabetai R. Mechanistic data from the VA Cooperative studies: ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias and plasma norepinephrine as determinants of prognosis in heart failure. Circulation. 1993;86:VI5–16.

    Google Scholar 

  25. Floras J. Clinical aspects of sympathetic activation and parasympathetic withdrawal in heart failure. J Am Coll Cardiol. 1993;4:72A–84A.

    Article  Google Scholar 

  26. Pehlivanidis AN, Athyros VG, Demitriadis DS, Papageorgiou AA, Bouloukos VJ, Kontopoulos AG. Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease. Atherosclerosis. 2001;151:463–9.

    Article  Google Scholar 

  27. Pliquett R, Cornish K, Zucker I. Statins: the effects on sympathetic nerve activity in heart failure. J Card Fail. 2001;7:16–26.

    Google Scholar 

  28. Pliquett RU, Cornish KG, Peuler JD, Zucker IH. Simvastatin normalizes autonomic neural control in experimental heart failure. Circulation. 2003;107:2493–8.

    Article  CAS  PubMed  Google Scholar 

  29. Bauersachs J, Galuppo P, Fraccarollo D, Christ M, Ertl G. Improvement of left ventricular remodelling and function by hydroxymethylglutaryl coenzyme A reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation. 2001;104:982–7.

    Article  CAS  PubMed  Google Scholar 

  30. Martin J, Denver R, Bailey M, Krum H. In vitro inhibitory effects of atorvastatin on cardiac fibroblasts: implications for ventricular remodelling. Clin Exp Pharmacol Physiol. 2005;32:697–701.

    Article  CAS  PubMed  Google Scholar 

  31. Grip O, Janciauskiene S, Lindgren S. Pravastatin down-regulates inflammatory mediators in human monocytes in vitro. Eur J Pharmacol. 2000;410:83–92.

    Article  CAS  PubMed  Google Scholar 

  32. Holm T, Andreassen AK, Ueland T, Kjekshus J, Frøland SS, Kjekshus E, et al. Effect of pravastatin on plasma markers of inflammation and peripheral endothelial function in male heart transplant recipients. Am J Cardiol. 2001;87:815–8.

    Article  CAS  PubMed  Google Scholar 

  33. Park JK, Müller DN, Mervaala EM, Dechend R, Fiebeler A, Schmidt F, et al. Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects. Kidney Int. 2000;58:1420–30.

    Article  CAS  PubMed  Google Scholar 

  34. Oi S, Haneda T, Osaki J, Kashiwagi Y, Nakamura Y, Kawabe J, et al. Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells. Eur J Pharmacol. 1999;376:139–48.

    Article  CAS  PubMed  Google Scholar 

  35. Hasegawa H, Yamamoto R, Takano H, Mizukami M, Asakawa M, Nagai T, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats. J Mol Cell Cardiol. 2003;35:953–60.

    Article  CAS  PubMed  Google Scholar 

  36. Kang P, Izumo S. Apoptosis and heart failure: a critical review of the literature. Circ Res. 2000;86:1107–13.

    Article  CAS  PubMed  Google Scholar 

  37. Kureishi Y, Luo Z, Shoijima I, Bialik A, Fulton D, Lefer DJ, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000;6:1004–10.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  38. Vaughan C, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet. 1996;348:1079–82.

    Article  CAS  PubMed  Google Scholar 

  39. Laufs U, La Fata V, Plutzky J, Liao J. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998;97:1129–35.

    Article  CAS  PubMed  Google Scholar 

  40. Feron O, Dessy C, Desager J, Balligand J. Hydroxy-methylglutarylcoenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation. 2001;103:113–8.

    Article  CAS  PubMed  Google Scholar 

  41. Vergnani L, Hatrik S, Ricci F, Passaro A, Manzoli N, Zuliani G. Effect of native and oxidized low-density lipoprotein on endothelial nitric oxide and superoxide production: key role of l arginine availability. Circulation. 2000;101:1261–6.

    Article  CAS  PubMed  Google Scholar 

  42. Horwich T, MacLellan W, Fonarow G. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol. 2004;43:642–8.

    Article  CAS  PubMed  Google Scholar 

  43. Folkeringa RJ, Van Kraaij DJ, Tieleman RG, Nieman FH, Pinto YM, Crijns HJ. Statins associated with reduced mortality in patients admitted for congestive heart failure. J Card Fail. 2006;12:134–8.

    Article  CAS  PubMed  Google Scholar 

  44. Foody JM, Shah R, Galusha D, Masoudi FA, Havranek EP, Krumholz HM. Statins and mortality among elderly patients hospitalized with heart failure. Circulation. 2006;113:1086–92.

    Article  CAS  PubMed  Google Scholar 

  45. Anker SD, Anker SD, Clark AL, Winkler R, Zugck C, Cicoira M, et al. Statin use and survival in patients with chronic heart failure—results from two observational studies with 5,200 patients. Int J Cardiol. 2006;112:234–42.

    Article  PubMed  Google Scholar 

  46. Sola S, Mir M, Rajagopalan S, Helmy T, Tandon N, Khan B. Statin therapy is associated with improved cardiovascular outcomes and levels of inflammatory markers in patients with heart failure. J Card Fail. 2005;11:607–12.

    Article  CAS  PubMed  Google Scholar 

  47. Ray J, Gong Y, Sykora K, Tu J. Statin use and survival outcomes in elderly patients with heart failure. Arch Intern Med. 2005;165:62–7.

    Article  CAS  PubMed  Google Scholar 

  48. Krum H, Latini R, Maggioni A, Anand I, Masson S, Carretta E, et al. Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT. Int J Cardiol. 2007;119:48–53.

    Article  PubMed  Google Scholar 

  49. Krum H, Bailey M, Meyer W, Verkenne P, Dargie H, Lechat P, et al. Impact of statin therapy on clinical outcomes in chronic heart failure patients according to β-blocker use: results of CIBIS II. Cardiology. 2006;8:28–34.

    Google Scholar 

  50. Segal R, Pitt B, Poole-Wilson PA, Sharma D, Bradstreet DC, Ikeda LS. Effects of HMG-CoA reductase inhibitors (statins) in patients with heart failure. Eur J Heart Fail. 2000;2 Suppl 2:96.

    Article  Google Scholar 

  51. Hognestad A, Dickstein K, Myhre E, Snappin S, Kjekshus J. Effect of combined statin and β-blocker treatment on one-year morbidity and mortality after myocardial infarction associated with heart failure. Am J Cardiol. 2004;93:603–6.

    Article  CAS  PubMed  Google Scholar 

  52. Ohara Y, Hiasa Y, Hosokawa S, Miyazaki S, Ogura R, Miyajima H, et al. Impact of hydroxymethylglutaryl coenzyme A reductase inhibition on left ventricular remodeling in patients with acute anterior myocardial infarction after primary coronary angioplasty. Int Heart J. 2005;46:987–95.

    Article  CAS  PubMed  Google Scholar 

  53. Tiefenbacher CP, Friedrich S, Bleeke T, Vahl C, Chen X, Niroomand F. ACE inhibitors and statins acutely improve endothelial dysfunction of human coronary arterioles. Am J Physiol Heart Circ Physiol. 2004;286:H1425–32.

    Article  CAS  PubMed  Google Scholar 

  54. Bates K, Ruggeroli CE, Goldman S, Gaballa MA. Simvastatin restores endothelial NO-mediated vasorelaxation in large arteries after myocardial infarction. Am J Physiol Heart Circ Physiol. 2002;283:H768–75.

    CAS  PubMed  Google Scholar 

  55. Correale M, Totaro A, Passero T, Abruzzese S, Musaico F, Ferraretti A, et al. Treatment with atorvastatin is associated with a better prognosis in chronic heart failure with systolic dysfunction: results from the Daunia Heart Failure Registry. Neth Heart J. 2013;21:408–16.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  56. Correale M, Brunetti ND, Totaro A, Montrone D, Russo AR, Fanigliulo AM, et al. Statin therapy blunts inflammatory activation and improves prognosis and left ventricular performance assessed by Tissue Doppler Imaging in subjects with chronic ischemic heart failure: results from the Daunia Heart Failure Registry. Clinics. 2011;66:777–84.

    PubMed Central  PubMed  Google Scholar 

  57. Correale M, Abruzzese S, Greco CA, Concilio M, Di Biase M, Brunetti ND. Statins in heart failure. Curr Vasc Pharmacol. 2012. http://www.ncbi.nlm.nih.gov/pubmed/23016898. Accessed 20 Sep 2012.

  58. Fukuta H, Sane D, Brucks S, Little W. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation. 2005;112:357–63.

    Article  CAS  PubMed  Google Scholar 

  59. Mozaffarian D, Minami E, Letterer RA, Lawler RL, McDonald GB, Levy WC. The effects of atorvastatin (10 mg) on systemic inflammation in heart failure. Am J Cardiol. 2005;96:1699–704.

    Article  CAS  PubMed  Google Scholar 

  60. Tousoulis D, Antoniades C, Vassiliadou C, Toutouza M, Pitsavos C, Tentolouris C, et al. Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure. Eur J Heart Fail. 2005;7:1126–32.

    Article  CAS  PubMed  Google Scholar 

  61. Strey CH, Young JM, Molyneux SL, George PM, Florkowski CM, Scott RS, et al. Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure. Atherosclerosis. 2005;179:201–6.

    Article  CAS  PubMed  Google Scholar 

  62. Tousoulis D, Antoniades C, Bosinakou E, Kotsopoulou M, Pitsavos C, Vlachopoulos C, et al. Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure. Atherosclerosis. 2005;178:359–63.

    Article  CAS  PubMed  Google Scholar 

  63. Tousoulis D, Antoniades C, Bosinakou E, Kotsopoulou M, Tsioufis C, Tentolouris C, et al. Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure. Heart. 2005;91:27–31.

    Article  CAS  PubMed  Google Scholar 

  64. Hamaad A, Sosin M, Lip GY, MacFadyen RJ. Short-term adjuvant atorvastatin improves frequency domain indices of heart rate variability in stable systolic heart failure. Cardiovasc Drugs Ther. 2005;19:183–7.

    Article  CAS  PubMed  Google Scholar 

  65. Lipinski MJ, Vetrovec GW, Gorelik D, Froelicher VF. The importance of heart rate recovery in patients with heart failure or left ventricular systolic dysfunction. J Cardiac Fail. 2005;11:624–30.

    Article  Google Scholar 

  66. Katircibasi MT, Canatar T, Kocum HT, Erol T, Tekin G, Demircan S, et al. Decreased heart rate recovery in patients with heart failure: effect of fluvastatin therapy. Int Heart J. 2005;46:845–54.

    Article  PubMed  Google Scholar 

  67. Cleland JG, Coletta AP, Nikitin NP, Clark AL. Clinical trials update from the American College of Cardiology: Darbepoetin alfa, ASTEROID, UNIVERSE, paediatric carvedilol, UNLOAD and ICELAND. Eur J Heart Fail. 2006;8:326–9.

    Article  CAS  PubMed  Google Scholar 

  68. Bleske BE, Nicklas JM, Bard RL, Brook RD, Gurbel PA, Bliden KP, et al. Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischaemic cardiomyopathy and average low density lipoprotein level. J Am Coll Cardiol. 2006;47:338–41.

    Article  CAS  PubMed  Google Scholar 

  69. Gissi-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1231–9.

    Article  Google Scholar 

  70. Lipinski MJ, Cauthen CA, Biondi-Zoccai GGL, Abbate A, Vrtovec B, Khan BV, et al. Meta-analysis of randomized controlled trials of statins versus placebo in patients with heart failure. Am J Cardiol. 2009;104:1708–16.

    Article  CAS  PubMed  Google Scholar 

  71. Zhang S, Zhang L, Sun A, Jiang H, Qian J, Ge J. Efficacy of statin therapy in chronic systolic cardiac insufficiency: a meta-analysis. Eur J Intern Med. 2011;22:478–84.

    Article  CAS  PubMed  Google Scholar 

  72. Nezasa K, Higaki K, Matsumura T, Inazawa K, Hasegawa H, Nakano M, et al. Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin. Drug Metab Dispos. 2002;30:1158–63.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of Interest

Luisa De Gennaro, Natale Daniele Brunetti, Michele Correale, Francesco Buquicchio, Pasquale Caldarola, and Matteo Di Biase declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Natale Daniele Brunetti.

Additional information

This article is part of the Topical Collection on Statin Drugs

Rights and permissions

Reprints and permissions

About this article

Cite this article

De Gennaro, L., Brunetti, N.D., Correale, M. et al. Statin Therapy in Heart Failure: For Good, for Bad, or Indifferent?. Curr Atheroscler Rep 16, 377 (2014). https://doi.org/10.1007/s11883-013-0377-x

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11883-013-0377-x

Keywords

Navigation